Stock listing
Frankfurt:UNC Ucb S.A. Aktie
German listing (Frankfurt) of Ucb S.A. · home listing Euronext:UCB
Follow Ucb S.A. into a list and get an email when it puts out news.
Share price · FWB:UNC
€277.80 EUR -8.30 (-2.9%)
Close on Nov 20, 2026
- Day range
- €277.80 – €282.40 EURNov 20, 2026
- Volume
- 60 sharesNov 20, 2026
- Market cap
- €52.97B EURAt the close on Nov 20, 2026 · price × 190.7M shares outstanding
- 52-week range
- €197.28 – €288.02 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €120,199 EURMedian day 28 shares · 23 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:UCB · Home | €279.60 EUR | -5.50 (-1.9%) | 252,719 | €280.50 | €283.70 | €277.40 | €285.10 | Close on Nov 20, 2026 |
| OTC:UCBJY | $151.52 USD | -3.44 (-2.2%) | 2,867 | $153.91 | $153.91 | $151.52 | $154.96 | Close on Nov 20, 2026 |
| OTC:UCBJF | $318.32 USD | -3.77 (-1.2%) | 19 | $318.32 | $318.32 | $318.32 | $322.09 | Close on Nov 20, 2026 |
| Frankfurt:UNC | €277.80 EUR | -8.30 (-2.9%) | 60 | €280.30 | €282.40 | €277.80 | €286.10 | Close on Nov 20, 2026 |
| Dusseldorf:UNC | €277.00 EUR | -4.80 (-1.7%) | — | €279.60 | €282.60 | €277.00 | €281.80 | Close on Nov 20, 2026 |
| Frankfurt:UNC0 | €140.00 EUR | -3.00 (-2.1%) | — | €140.00 | €140.00 | €140.00 | €143.00 | Close on Nov 20, 2026 |
| Munich:UNC | €279.50 EUR | -7.50 (-2.6%) | — | €280.30 | €280.30 | €279.50 | €287.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:UNC · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €288.02 | +0.802 | +0.3% | €288.02 | €288.02 | €288.02 | 85 | |
| €287.22 | +12.01 | +4.4% | €284.40 | €287.27 | €283.86 | 666 | |
| €275.20 | +1.675 | +0.6% | €275.20 | €275.20 | €275.20 | 790 | |
| €273.53 | -5.46 | -2.0% | €273.53 | €273.53 | €273.53 | 10 | |
| €278.99 | +0.292 | +0.1% | €279.00 | €279.00 | €278.95 | 329 | |
| €278.70 | +12.20 | +4.6% | €276.97 | €279.03 | €276.51 | 580 | |
| €266.50 | -2.251 | -0.8% | €266.50 | €266.50 | €266.50 | 17,006 | |
| €268.75 | -0.268 | -0.1% | €268.82 | €268.82 | €268.75 | 59 | |
| €269.02 | -2.267 | -0.8% | €269.02 | €269.02 | €269.02 | 271 | |
| €271.28 | +4.282 | +1.6% | €271.57 | €272.16 | €269.11 | 2,154 | |
| €267.00 | +10.40 | +4.1% | €259.25 | €268.29 | €257.42 | 217 | |
| €256.60 | +40.28 | +18.6% | €229.59 | €257.00 | €228.03 | 425 | |
| €216.31 | -0.287 | -0.1% | €216.48 | €217.13 | €215.54 | 150 | |
| €216.60 | +13.66 | +6.7% | €206.58 | €217.22 | €205.08 | 150 | |
| €202.95 | -0.511 | -0.3% | €202.95 | €202.95 | €202.95 | 0 | |
| €203.46 | -1.389 | -0.7% | €206.28 | €206.38 | €201.96 | 0 | |
| €204.85 | +7.567 | +3.8% | €202.59 | €204.98 | €199.69 | 167 | |
| €197.28 | -7.049 | -3.4% | €197.28 | €197.28 | €197.28 | 0 | |
| €204.33 | +0.303 | +0.1% | €202.99 | €205.85 | €202.92 | 10 | |
| €204.03 | +1.538 | +0.8% | €204.13 | €204.65 | €203.61 | 20 | |
| €202.49 | -0.505 | -0.2% | €202.49 | €202.49 | €202.49 | 136 | |
| €202.99 | +1.481 | +0.7% | €203.72 | €203.94 | €201.91 | 40 | |
| €201.51 | +0.83 | +0.4% | €202.41 | €202.70 | €201.51 | 10 | |
| €200.68 | -3.40 | -1.7% | €201.63 | €201.79 | €198.57 | 87 | |
| €204.08 | -0.316 | -0.2% | €204.08 | €204.08 | €204.08 | 0 | |
| €204.40 | -0.015 | 0.0% | €204.40 | €204.40 | €204.40 | 292 | |
| €204.41 | -1.974 | -1.0% | €204.41 | €204.41 | €204.41 | 0 | |
| €206.39 | -5.668 | -2.7% | €207.61 | €208.23 | €204.07 | 335 | |
| €212.05 | -2.886 | -1.3% | €212.05 | €212.05 | €212.05 | 0 | |
| €214.94 | +0.775 | +0.4% | €214.91 | €214.95 | €214.90 | 33 | |
| €214.17 | +4.188 | +2.0% | €212.39 | €215.08 | €211.19 | 472 | |
| €209.98 | -3.989 | -1.9% | €209.98 | €209.98 | €209.98 | 0 | |
| €213.97 | +2.128 | +1.0% | €213.97 | €213.97 | €213.97 | 0 | |
| €211.84 | +3.055 | +1.5% | €211.84 | €211.84 | €211.84 | 0 | |
| €208.78 | +2.013 | +1.0% | €208.78 | €208.78 | €208.78 | 0 | |
| €206.77 | +1.114 | +0.5% | €206.77 | €206.77 | €206.77 | 723 | |
| €205.66 | -3.85 | -1.8% | €205.66 | €205.66 | €205.66 | 0 | |
| €209.51 | -1.011 | -0.5% | €209.51 | €209.51 | €209.51 | 0 | |
| €210.52 | +4.263 | +2.1% | €210.52 | €210.52 | €210.52 | 0 | |
| €206.25 | +6.739 | +3.4% | €206.25 | €206.25 | €206.25 | 0 | |
| €199.52 | -3.426 | -1.7% | €199.52 | €199.52 | €199.52 | 596 | |
| €202.94 | -1.981 | -1.0% | €202.94 | €202.94 | €202.94 | 0 | |
| €204.92 | -1.353 | -0.7% | €206.26 | €207.03 | €202.32 | 55 | |
| €206.28 | -3.06 | -1.5% | €208.81 | €208.91 | €205.41 | 30 | |
| €209.34 | -10.14 | -4.6% | €209.34 | €209.34 | €209.34 | 0 | |
| €219.47 | +0.898 | +0.4% | €219.47 | €219.47 | €219.47 | 352 | |
| €218.57 | -1.067 | -0.5% | €218.57 | €218.57 | €218.57 | 0 | |
| €219.64 | +0.208 | +0.1% | €219.64 | €219.64 | €219.64 | 0 | |
| €219.43 | +4.412 | +2.1% | €216.92 | €222.19 | €215.93 | 69 | |
| €215.02 | -6.073 | -2.7% | €215.02 | €215.02 | €215.02 | 0 | |
| €221.09 | -0.403 | -0.2% | €221.09 | €221.09 | €221.09 | 2 | |
| €221.50 | -3.347 | -1.5% | €221.50 | €221.50 | €221.50 | 0 | |
| €224.84 | +5.683 | +2.6% | €224.84 | €224.84 | €224.84 | 0 | |
| €219.16 | -1.404 | -0.6% | €219.16 | €219.16 | €219.16 | 0 | |
| €220.57 | +3.189 | +1.5% | €220.57 | €220.57 | €220.57 | 0 | |
| €217.38 | -2.167 | -1.0% | €217.38 | €217.38 | €217.38 | 28 | |
| €219.54 | +3.962 | +1.8% | €220.34 | €220.55 | €217.14 | 35 |
- Ticker
- Frankfurt:UNC
- Asset type
- Stock
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 30, 2026
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX (bimekizumab) for treating hidradenitis suppurativa
Latest deck · Jul 30, 2026
H1 2026 Earnings Presentation
Earnings · 22 slides
Latest news
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX (bimekizumab) for treating hidradenitis suppurativa
Sep 30, 2026
Closed €206.39 (-2.7%) on Sep 30, 2026
UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
Sep 29, 2026
Closed €212.05 (-1.3%) on Sep 29, 2026
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
Sep 9, 2026
Closed €204.92 (-0.7%) on Sep 9, 2026
UCB Comes to Agreement with U.S. Government to Lower the Cost of Medicine and Strengthen U.S. Manufacturing
Aug 31, 2026
Closed €219.43 (+2.1%) on Sep 1, 2026
Transparency notification Wellington Management Group LLP
Aug 31, 2026
Closed €219.43 (+2.1%) on Sep 1, 2026
Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
Aug 5, 2026
Closed €230.56 (+3.8%) on Aug 6, 2026
UCB Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase
Jul 30, 2026
Closed €224.18 (-9.9%) on Jul 30, 2026
UCB presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026
Jul 8, 2026
Closed €251.56 (+0.1%) on Jul 8, 2026
FASTRAX working session highlights progress in axSpA diagnosis
Jul 3, 2026
Closed €264.14 (+2.0%) on Jul 3, 2026
UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline
Jun 17, 2026
Closed €247.99 (-2.3%) on Jun 17, 2026
Ucb S.A. on 6ix
- News releases
- 29 in the last 12 months · 39 in all · newest Sep 30, 2026 · oldest 2025
- Decks
- 41 decks · latest Jul 30, 2026
Where Ucb S.A. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:UCB · Home listing | Euronext | Belgium | EUR |
| OTC:UCBJY | OTC | United States | USD |
| gettex:UNC | gettex | Germany | EUR |
| OTC:UCBJF | OTC | United States | USD |
| LSIN:0NZT | LSIN | United Kingdom | EUR |
| Xetra:UNC | Xetra | Germany | EUR |
| BX Swiss:UNC | BX Swiss | Switzerland | CHF |
| Tradegate:UNC | Tradegate | Germany | EUR |
| Lang & Schwarz:852738 | Lang & Schwarz | Germany | EUR |
| LS Exchange:852738 | LS Exchange | Germany | EUR |
| EUROTLX:4UCB | EUROTLX | Italy | EUR |
| VIE:UCB | Vienna | Austria | EUR |
| Frankfurt:UNC · This page | Frankfurt | Germany | EUR |
| Dusseldorf:UNC | Dusseldorf | Germany | EUR |
| Frankfurt:UNC0 | Frankfurt | Germany | EUR |
| Turquoise:UCBB | Turquoise | United Kingdom | EUR |
| Munich:UNC | Munich | Germany | EUR |
| Aquis:UCBB | Aquis | United Kingdom | EUR |
| Hamburg:UNC | Hamburg | Germany | EUR |
| Aquis:UCBB | Aquis | United Kingdom | EUR |
| BIVA:UCBN | BIVA | Mexico | MXN |
| BMV:UCBN | BMV | Mexico | MXN |
| Dusseldorf:UNC0 | Dusseldorf | Germany | EUR |
| Lang & Schwarz:A14WZY | Lang & Schwarz | Germany | EUR |
| LS Exchange:A14WZY | LS Exchange | Germany | EUR |
| Stuttgart:UNC | Stuttgart | Germany | EUR |
| Stuttgart:UNC0 | Stuttgart | Germany | EUR |
| Hanover:UNC | Hanover | Germany | EUR |
Valuation
Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €56.10B EUR
- P/E
- 34.2×
- EV/sales
- 7.3×
- EV/EBITDA
- 31.3×
- Price/book
- 4.6×
- Gross margin
- 71.1%
- Operating margin
- 15.1%
- Net margin
- 20.1%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 298.63 EUR · Analysts' mean
- EPS, year to Dec 2026
- 13.19 · 17 analysts
- Revenue, year to Dec 2026
- 9.1B · 16 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jean-Christophe Tellier | Chief Executive Officer & Chairman of the Executive Committee |
| Sandrine Dufour | Executive Vice President, Chief Financial Officer |
| Denelle J. Waynick Johnson | Executive Vice President & General Counsel |
| Anna Clark | Corporate Communications, Media Relations |
| Antje Witte | Investor Relations |
| Fayos Alonso | Corporate Communications, Media Relations |
| Laurent Schots | Corporate Communications, Media Relations |
| Sahar Yazdian | Corporate Communications |
| Yvonne Naughton | Investor Relations |
| Alistair Henry | Executive Vice President & Chief Scientific Officer |
| Emmanuel Caeymaex | Executive Vice President |
| Fiona du Monceau | Executive Vice President, Chief Commercial Officer |
| Jacques Marbehant | Executive Vice President, Patient Supply |
| Jean Luc Fleurial | Executive Vice President & Chief Human Resources Officer |
Board
| Director | Role |
|---|---|
| Jonathan Peacock | Independent Director, Chair of the Board |
| Cédric van Rijckevorsel | Director |
| Charles-Antoine Janssen | Director, Vice-chair of the Board |
| Cyril Janssen | Director |
| Dolca Thomas | Independent Director |
| Fiona Powrie | Independent Director |
| Jan Berger | Independent Director |
| Jean-Christophe Tellier | Chief Executive Officer & Chairman of the Executive Committee |
| Judy Brown | Independent Director, Chair of the Audit Committee |
| Maëlys Castella | Independent Director |
| Nefertiti Greene | Independent Director |
| Pierre Gurdjian | Independent Director |
| Stef Heylen | Director |
| Ulf Wiinberg | Independent Director |
Events
- Next results
- Feb 25, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Dec 31, 2025 | −1.2% |
| Quarter to Sep 30, 2025 | Nov 28, 2025 | +0.5% |
| Q2 2025 | Jul 31, 2025 · After close | −2.9% |
| Quarter to Mar 31, 2025 | May 30, 2025 | +4.3% |
| Q4 2024 | Feb 27, 2025 | −0.3% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | +1.9% |
| Q2 2024 | Jul 25, 2024 | +3.8% |
| Quarter to Mar 31, 2024 | Apr 25, 2024 · After close | −0.4% |
| Q4 2023 | Feb 28, 2024 · After close | +1.4% |
| Quarter to Sep 30, 2023 | Oct 31, 2023 | −1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 27, 2023 · Before open | +0.1% |
| Q1 2023 | Apr 26, 2023 | −2.7% |
| Q4 2022 | Feb 22, 2023 · Before open | +2.4% |
| Q3 2022 | Nov 1, 2022 | +0.2% |
| Q2 2022 | Jul 28, 2022 · Before open | −4.0% |
| Q1 2022 | Apr 27, 2022 | +2.1% |
| Q4 2021 | Feb 24, 2022 | +8.7% |
| Q3 2021 | Nov 2, 2021 | +2.5% |
| Q2 2021 | Jul 28, 2021 · After close | +1.4% |
| Q1 2021 | Apr 28, 2021 | −2.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 22 slides | Jul 30, 2026 |
| FY2025 Earnings Presentation | Earnings | 22 slides | Feb 26, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 16 slides | Jan 14, 2026 |
| H1 2025 Earnings Presentation | Earnings | 21 slides | Jul 31, 2025 |
| FY2024 Earnings Presentation | Earnings | 18 slides | Feb 27, 2025 |
| 43rd Annual J.P. Morgan Healthcare Conference (January 2025) | Conference | 13 slides | Jan 15, 2025 |
| ESG Presentation (November 2024) | Sustainability | 48 slides | November 2024 |
| H1 2024 Earnings Presentation | Earnings | 19 slides | Jul 25, 2024 |
| FY2023 Earnings Presentation | Earnings | 22 slides | Feb 28, 2024 |
| 42nd Annual J.P. Morgan Healthcare Conference (January 2024) | Conference | 10 slides | Jan 9, 2024 |
All 41 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ESG Presentation (November 2023) | Sustainability | 51 slides | November 2023 |
| H1 2023 Earnings Presentation | Earnings | 19 slides | Jul 27, 2023 |
| Technical Presentation (March 2023) | Technical | 32 slides | March 2023 |
| FY2022 Earnings Presentation | Earnings | 42 slides | Feb 22, 2023 |
| Investor Day (January 2023) | Investor day | 29 slides | Jan 9, 2023 |
| ESG Presentation (November 2022) | Sustainability | 50 slides | November 2022 |
| Technical Presentation (November 2022) | Technical | 40 slides | November 2022 |
| 31st EADV Congress 2022 | Conference | 40 slides | September 2022 |
| H1 2022 Earnings Presentation | Earnings | 30 slides | Jul 28, 2022 |
| Technical Presentation (May 2022) | Technical | 59 slides | May 2022 |
| FY2021 Earnings Presentation | Earnings | 37 slides | Feb 24, 2022 |
| Merger or Acquisition (January 2022) | Merger or acquisition | 22 slides | Jan 19, 2022 |
| H1 2021 Earnings Presentation | Earnings | 32 slides | Jul 29, 2021 |
| Shareholder Meeting (April 2021) | Shareholder meeting | 12 slides | Apr 29, 2021 |
| Investor Presentation (June 2020) | Investor deck | 63 slides | June 2020 |
| H1 2019 Earnings Presentation | Earnings | 50 slides | Jul 25, 2019 |
| FY2017 Earnings Presentation | Earnings | 53 slides | Feb 22, 2018 |
| H1 2017 Earnings Presentation | Earnings | 41 slides | Jul 27, 2017 |
| Q1 2017 Earnings Presentation | Earnings | 37 slides | Apr 24, 2017 |
| Q1 2016 Earnings Presentation | Earnings | 41 slides | Apr 25, 2016 |
| Investor Presentation (September 2014) | Investor deck | 40 slides | September 2014 |
| FY2013 Earnings Presentation | Earnings | 44 slides | Feb 26, 2014 |
| Investor Presentation (April 2011) | Investor deck | 63 slides | April 2011 |
| H1 2010 Earnings Presentation | Earnings | 60 slides | Aug 2, 2010 |
| H1 2010 Earnings Presentation | Earnings | 62 slides | Aug 2, 2010 |
| FY2009 Earnings Presentation | Earnings | 68 slides | Mar 2, 2010 |
| H1 2009 Earnings Presentation | Earnings | 45 slides | Jul 31, 2009 |
| Investor Presentation (June 2009) | Investor deck | 47 slides | June 2009 |
| Technical Presentation (2009) | Technical | 24 slides | 2009 |
| Technical Presentation (2009) | Technical | 25 slides | 2009 |
| Investor Presentation (November 2008) | Investor deck | 42 slides | November 2008 |
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.74B | 6.15B | 5.25B | 5.52B | 5.78B | 5.35B | 4.91B | 4.63B | 4.47B | 4.15B |
| Cost of revenue | 2.23B | 1.75B | 1.71B | 1.67B | 1.44B | 1.36B | 1.43B | 1.20B | 1.20B | 1.20B |
| Gross profit | 5.51B | 4.40B | 3.54B | 3.84B | 4.34B | 3.98B | 3.49B | 3.43B | 3.27B | 2.94B |
| Research and development | 1.82B | 1.78B | 1.63B | 1.67B | 1.63B | 1.57B | 1.27B | 1.16B | 1.06B | 1.02B |
| Selling, general and administrative | 264.0M | 272.0M | 230.0M | 225.0M | 208.0M | 196.0M | 195.0M | 180.0M | 192.0M | 184.0M |
| Operating income | 1.17B | 1.32B | 604.0M | 585.0M | 1.28B | 971.0M | 1.08B | 1.11B | 1.07B | 796.0M |
| Depreciation and amortization | 627.0M | 641.0M | 691.0M | 589.0M | 323.0M | 354.0M | 313.0M | 288.0M | 234.0M | 232.0M |
| EBITDA | 1.79B | 1.97B | 1.29B | 1.17B | 1.61B | 1.32B | 1.40B | 1.40B | 1.31B | 1.03B |
| Interest expense | 128.0M | 200.0M | 210.0M | 112.0M | 138.0M | 107.0M | 60.0M | 62.0M | 56.0M | 87.0M |
| Income before tax | 1.82B | 1.16B | 441.0M | 511.0M | 1.23B | 880.0M | 961.0M | 1.01B | 988.0M | 764.0M |
| Income tax | 264.0M | 98.0M | 98.0M | 91.0M | 170.0M | 119.0M | 146.0M | 200.0M | 218.0M | 199.0M |
| Net income | 1.56B | 1.06B | 343.0M | 418.0M | 1.06B | 732.0M | 792.0M | 800.0M | 753.0M | 520.0M |
| Earnings per share, basic | 8.20 | 5.61 | 1.81 | 2.20 | 5.60 | 3.87 | 4.23 | 4.24 | 4.00 | 2.76 |
| Earnings per share, diluted | 5.48 | 1.76 | 2.14 | 5.45 | 3.77 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.25B | 1.57B | 861.0M | 899.0M | 1.26B | 1.34B | 329.0M | 1.26B | 1.05B | 761.0M |
| Short-term investments | 219.0M | 184.0M | 108.0M | 170.0M | 110.0M | 704.0M | 989.0M | 17.0M | 14.0M | 46.0M |
| Receivables | 1.79B | 1.53B | 1.22B | 1.05B | 1.24B | 1.03B | 707.0M | 632.0M | 738.0M | 820.0M |
| Inventory | 1.50B | 1.31B | 1.03B | 907.0M | 878.0M | 854.0M | 780.0M | 647.0M | 597.0M | 578.0M |
| Current assets | 6.05B | 4.79B | 3.44B | 3.30B | 3.71B | 3.58B | 3.29B | 2.95B | 2.68B | 2.33B |
| Property, plant and equipment | 1.75B | 1.59B | 1.43B | 1.27B | 1.03B | 840.0M | 805.0M | 673.0M | 678.0M | |
| Goodwill | 5.09B | 5.46B | 5.25B | 5.34B | 5.17B | 4.96B | 5.06B | 4.97B | 4.84B | 5.18B |
| Total assets | 18.2B | 17.3B | 15.5B | 15.9B | 14.2B | 13.3B | 11.1B | 10.5B | 9.92B | 10.2B |
| Accounts payable | 817.0M | 3.02B | 2.31B | 2.49B | 2.56B | 2.14B | 403.0M | 364.0M | 281.0M | 274.0M |
| Current liabilities | 4.40B | 3.53B | 2.62B | 3.11B | 2.82B | 2.81B | 2.39B | 2.15B | 1.95B | 2.42B |
| Long-term debt | 2.06B | 2.82B | 2.88B | 2.54B | 1.25B | 1.63B | 914.0M | 1.29B | 1.53B | 1.57B |
| Total debt | 2.25B | 3.03B | 3.04B | 2.90B | 1.31B | 1.71B | 1.28B | 1.50B | 1.57B | 1.60B |
| Total liabilities | 7.29B | 7.32B | 6.56B | 6.80B | 5.82B | 6.05B | 4.07B | 4.26B | 4.18B | 4.74B |
| Shareholders' equity | 10.9B | 10.0B | 8.97B | 9.06B | 8.39B | 7.27B | 7.04B | 6.31B | 5.81B | 5.58B |
| Shares outstanding | 190.0M | 195.0M | 195.2M | 194.8M | 194.2M | 194.2M | 187.2M | 188.5M | 188.3M | 188.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.16B | 1.24B | 761.0M | 1.12B | 1.55B | 1.08B | 882.0M | 1.09B | 927.0M | 427.0M |
| Capital spending | -281.0M | -234.0M | -238.0M | -252.0M | -282.0M | -256.0M | -294.0M | -94.0M | -100.0M | -108.0M |
| Free cash flow | 1.88B | 1.01B | 523.0M | 867.0M | 1.27B | 825.0M | 588.0M | 995.0M | 827.0M | 319.0M |
| Cash from investing | -389.0M | 282.0M | -440.0M | -1.58B | -487.0M | -2.23B | -235.0M | -320.0M | -228.0M | 317.0M |
| Cash from financing | -1.09B | -818.0M | -308.0M | 70.0M | -1.12B | 1.18B | -605.0M | -538.0M | -402.0M | -1.27B |
| Dividends paid | -264.0M | -259.0M | -252.0M | -247.0M | -240.0M | -235.0M | -228.0M | -222.0M | -217.0M | -231.0M |
| Share buybacks | -121.0M | -162.0M | -40.0M | -42.0M | -60.0M | -106.0M | -77.0M | -51.0M | -105.0M | -49.0M |
| Change in cash | 678.0M | 706.0M | 13.0M | -391.0M | -53.0M | 30.0M | 51.0M | 215.0M | 266.0M | -521.0M |
Cap table
Built by 6ix from Ucb S.A.’s releases
- Common shares
- 190,662,572
- Fully diluted
- 190,662,572
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 190,662,572 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 190,662,572 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alistair Henry | Executive Vice President & Chief Scientific Officer · Since at least May 7, 2026 |
| Anna Clark | Corporate Communications, Media Relations · Since at least Jun 2, 2026 |
| Antje Witte | Investor Relations · Since at least Aug 5, 2026 |
| Cédric van Rijckevorsel | Director · Since at least Apr 30, 2026 |
| Charles-Antoine Janssen | Director, Vice-chair of the Board · Since at least Nov 6, 2026 |
| Cyril Janssen | Director · Since at least Nov 6, 2026 |
| Denelle J. Waynick Johnson | Executive Vice President & General Counsel · Since at least Nov 6, 2026 |
| Dolca Thomas | Independent Director · Since at least Nov 6, 2026 |
| Emmanuel Caeymaex | Executive Vice President · Since at least Nov 6, 2026 |
| Fayos Alonso | Corporate Communications, Media Relations · Since at least Jun 17, 2026 |
All 27 people
| Person | Seat |
|---|---|
| Fiona du Monceau | Executive Vice President, Chief Commercial Officer · Since at least Jun 27, 2025 |
| Fiona Powrie | Independent Director · Since at least Nov 6, 2026 |
| Jacques Marbehant | Executive Vice President, Patient Supply · Since at least Nov 6, 2026 |
| Jan Berger | Independent Director · Since at least Nov 6, 2026 |
| Jean-Christophe Tellier | Chief Executive Officer & Chairman of the Executive Committee · Since at least Aug 31, 2026 |
| Jean Luc Fleurial | Executive Vice President & Chief Human Resources Officer · Since at least Nov 6, 2026 |
| Jonathan Peacock | Independent Director, Chair of the Board · Since at least Apr 30, 2026 |
| Judy Brown | Independent Director, Chair of the Audit Committee · Since at least Apr 30, 2026 |
| Laurent Schots | Corporate Communications, Media Relations · Since at least Sep 29, 2026 |
| Maëlys Castella | Independent Director · Since at least Nov 6, 2026 |
| Nefertiti Greene | Independent Director · Since at least Nov 6, 2026 |
| Pierre Gurdjian | Independent Director · Since at least Nov 6, 2026 |
| Sahar Yazdian | Corporate Communications · Since at least Sep 30, 2026 |
| Sandrine Dufour | Executive Vice President, Chief Financial Officer · Since at least Jul 30, 2026 |
| Stef Heylen | Director · Since at least Nov 6, 2026 |
| Ulf Wiinberg | Independent Director · Since at least Nov 6, 2026 |
| Yvonne Naughton | Investor Relations · Since at least Sep 30, 2026 |
Log in to ask 6ix AI your own questions about Ucb S.A.